Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
TCT 2025: INFINITY-SWEDEHEART: Long-Term Bioadaptor Outcomes
Author(s): David Erlinge Added: 6 months ago
TCT 2025 - Findings from INFINITY-SWEDEHEART show significant reductions in target vessel failure and treatment benefit after 6 months to two years with the DynamX bioadaptor stent.Prof David Erlinge (Skane University Hospital, SE) joins us to discuss findings from the INFINITY-SWEDEHEART trial, a prospective, multicenter, registry-based randomized clinical trial comparing long-term outcomes of… View more

Intervention

MI/ACS
30th Annual Meeting of the ISCP
Author(s): Daniel García Iglesias , Fernando López Iglesias , Rodrigo Ariel di Massa , et al Added: 1 month ago

Imaging & Diagnostics

Prevention & Chronic Conditions
AHA 25: HFpEF as an Adipose Tissue Disorder
Author(s): Milton Packer Added: 6 months ago
AHA Scientific Sessions 2025 - Dr Milton Packer (Baylor University Medical Center, US) joins us to discuss his novel unifying hypothesis that heart failure with preserved ejection fraction arises primarily from visceral adipose tissue dysfunction and altered adipokine signaling, rather than as a heterogeneous disorder driven by multiple comorbidities.Interview Questions:Can you explain the core… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Semaglutide Modulates Key Pathways to Resolve MASH, Proteomic Analysis Reveals
Added: 9 months ago Source:  Radcliffe CVRM
A new study has explored the underlying mechanisms by which semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), improves outcomes in patients with metabolic dysfunction-associated steatohepatitis (MASH).¹ The research, which combined analysis of a phase 2 clinical trial with preclinical models, identified a unique proteomic signature associated with treatment and suggests that… View more

Cardiovascular Kidney Metabolic
TCT 24: The INFINITY-SWEDEHEART Trial
Author(s): David Erlinge Added: 1 year ago
TCT Conference 2024 - Significant reduction in TLF and TVF and flattening of event curves after 6 months in favour of DynamX Bioadaptor.Dr David Erlinge (Skane University Hospital, Lund, SE) joins us onsite at TCT Conference to discuss the findings from INFINITY-SWEDEHEART (NCT04562805).INFINITY-SWEDEHEART is a prospective, multicenter, randomized registry-based clinical trial, where patients… View more

Intervention
30th Annual Meeting of the ISCP
Author(s): Miguel García-Villarino , Elias Delgado , Carmen Lambert , et al Added: 1 month ago

Prevention & Chronic Conditions

Demographic
EuroPCR 25: BIOADAPTOR RCT 3Y Outcomes
Author(s): Shigeru Saito Added: 12 months ago
EuroPCR25 - Novel DynamX Bioadaptor demonstrates a sustained reduction of device-related events from six-month to three-year follow-up compared to drug-eluting stents (DES).We are joined by Dr Shigeru Saito (Shonan Kamakura General Hospital, Kamakura, JP) to discuss key findings from the BIOADAPTOR RCT trial (NCT04192747). This prospective, randomised controlled trial compared the ELX1805J … View more

Intervention

Vascular Disease and Surgery
30th Annual Meeting of the ISCP
Author(s): Andrés Álvarez , Diego Manuel de la Eranueva , Manuel Sánchez , et al Added: 1 month ago

Prevention & Chronic Conditions
DrPaolo Canova, MD obtained his medical degree with full honours at Milan-Bicocca University in 2008. During his studies he won a scholarship for a cooperation and development project at “St. Mary’ s Lacor Hospital” (Uganda) and completed a clinical fellowship in Internal Medicine and Cardiology at the “Hospital Universitario Marques de Valdecilla” in Santander (Spain). Between 2009 and 2014… View more